Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Martin W. Schoen, MDMPH, Peter Georgantopoulos, MS, Nagasai S Yalavarthi, BS, Charles L. Bennett, MD PhD

Blood (2019) 134 (Supplement_1): 2135.

https://doi.org/10.1182/blood-2019-121770

Published: 2019

Journal Articles

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Kevin Knopf, MD, William Hrureshky, Bryan Love, Leann Norris, Charles L. Bennett, MD PhD

Blood (2018) 132 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2018-99-119724

Published: 2018

Journal Articles

Trends of Palliative Care Utilization in Acute Myeloid Leukemia in the United States

Sri Harsha Tella, MD, Anuhya Kommalapati, MD, Charles L. Bennett, MD PhD, Gaurav Goyal, MBBS

Blood (2018) 132 (Supplement 1): 4767.

https://doi.org/10.1182/blood-2018-99-110681

Published: 2018

Journal Articles

Filgrastim Biosimilar: Curb Your Enthusiasm in the US, and Celebrate in the EU, Canada, and Japan

Charles L. Bennett, MD PhD, Ashley Caitlin Godwin, B.S.

Blood (2017) 130 (Supplement 1): 5625.

https://doi.org/10.1182/blood.V130.Suppl_1.5625.5625

Published: 2017

Journal Articles

Darbepoetin Hits a Double As Epoetin Hits a Home Run in Response to the 2007 FDA Black Box Warning

Virginia Noxon, Charles L. Bennett, MD PhD

Blood (2015) 126 (23): 2075.

https://doi.org/10.1182/blood.V126.23.2075.2075

Published: 2015

Journal Articles

Introduction of a Quick Assay for ADAMTS13 Activity Improved a Survival of Acquired TTP Patients Who Received Platelet Transfusions

Yumi Yoshii, MD, Masanori Matsumoto, MD PhD, Kurumatani Norio, MD PhD, Ayami Isonishi, BS, Masahito Uemura, MD PhD, Yuji Hori, PhD, Masaki Hayakawa, MD, Hideo Yagi, MD PhD, Charles L Bennett, MD PhD MPP, Yoshihiro Fujimura, MD PhD

Blood (2014) 124 (21): 4209.

https://doi.org/10.1182/blood.V124.21.4209.4209

Published: 2014

Journal Articles

Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012)

Craig S Boddy, MD, Charles L Bennett, MD PhD MPP, LeAnn B Norris, PharmD, Peter Georgantopoulos, MPH, MA, Suhong Luo, MPH, Kenneth R Carson, MD

Blood (2014) 124 (21): 4456.

https://doi.org/10.1182/blood.V124.21.4456.4456

Published: 2014

Journal Articles

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Charles L. Bennett, MD PhD, Sony Jacob, MD, Peter Georgantopoulos, MPH, MA, Judy Nichols, MSN, ACNP, Iain C Macdougall, MD

Blood (2014) 124 (21): 3516.

https://doi.org/10.1182/blood.V124.21.3516.3516

Published: 2014

Journal Articles

Forewarned Is Forearmed- Comparison of Southern Network on Adverse Reactions (SONAR) Versus an FDA-Mandated Prospective Observational Registry Assessment of Gemtuzumab Ozogamycin-Associated Sinusoidal Obstructive Syndrome

Jametta Magwood, BA, Peter Georgantopoulos, MPH, MA, LeAnn B Norris, PharmD, Charles L. Bennett, MD PhD

Blood (2014) 124 (21): 5970.

https://doi.org/10.1182/blood.V124.21.5970.5970

Published: 2014

Journal Articles

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Virginia Noxon, Charles L Bennett, MD PhD MPP, Jun Wu

Blood (2014) 124 (21): 1276.

https://doi.org/10.1182/blood.V124.21.1276.1276

Published: 2014

Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB

Blood (2013) 122 (21): 5612.

https://doi.org/10.1182/blood.V122.21.5612.5612

Published: 2013

Journal Articles

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Alyssa Trenery, Samuel Kessler, BA, Van Slooten Eleasa, BS, Akida Lebby, Charles L. Bennett, MD, PhD, MPP, Paul Yarnold, PhD, Paul Ray, DO, MA, Dennis W. Raisch, PhD, MS, RPh, Gowtham Rao, MD, PhD, Peter Georgantopoulos, MPH, MA, LeAnne Norris, PharmD, Simone Boyle, BA, Ashlyn Byrne, Matthew Bialkowski, Oliver Sartor, MD

Blood (2013) 122 (21): 2938.

https://doi.org/10.1182/blood.V122.21.2938.2938

Published: 2013

Journal Articles

Connecticut Attorney General Blumenthal's Citizen Petition Regarding Thalidomide-Associated VTE Redux: Patient Safety Concerns Still Persist.

June M. McKoy, MD, JD, MPH, Monica Boen, BA, Dianne Deleon, BA, Josephine Feliciano, MD, D. Mark Courtney, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 3990.

https://doi.org/10.1182/blood.V114.22.3990.3990

Published: 2009

Journal Articles

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

Charles L Bennett, MD, PhD, Athena T Samaras, BA, June M McKoy, MD, JD, MPH, Beatrice J Edwards, MD, FACP, Mi Zheng, Matthew J Fisher, BA, Simone N Boyle, BA, Steven M Trifilio, RPh, Monica Boen, BA, Dianne Deleon, BA, Dennis P West, PhD

Blood (2009) 114 (22): 4538.

https://doi.org/10.1182/blood.V114.22.4538.4538

Published: 2009

Journal Articles

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Charles L. Bennett, MD, PhD, Ari Polish, MD, Athena T Samaras, BA, Mi Zheng, Dennis P West, PhD, Steven M Trifilio, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Matthew J Fisher, June M McKoy, MD, JD, MPH

Blood (2009) 114 (22): 4555.

https://doi.org/10.1182/blood.V114.22.4555.4555

Published: 2009

Journal Articles

Reactivation of Hepatitis B Virus (HBV) Associated with Rituximab Use in Lymphoma: Under Reporting and Lack of Data Quality Reported to the FDA.

Andrew M. Evens, DO, MSc, Bara Fintel, Brian Chiu, PhD, Leo I. Gordon, MD, Daniel Ganger, MD, Laura Kulik, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 1370.

https://doi.org/10.1182/blood.V114.22.1370.1370

Published: 2009

Journal Articles

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Anaadriana Zakarija, MD, Thanh Ha Luu, Hau C. Kwaan, MD, PhD, June McKoy, MD, JD, MPH, Ivy Weiss, BS, Paul Yarnold, Nicholas Bandarenko, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 892.

https://doi.org/10.1182/blood.V114.22.892.892

Published: 2009

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

Multiple Non-Linear Epitopes of ADAMTS13 Were Targeted by Anti- ADAMTS13 IgG in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

Dezhi Shang, Haifeng Wu, Spero Cataland, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, X. Long Zheng

Blood (2008) 112 (11): 276.

https://doi.org/10.1182/blood.V112.11.276.276

Published: 2008

Journal Articles

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

Wendy Oatis, MD, JD, Veena Shankaran, MD, Faisal Saghir, MD, Charles L. Bennett, MD, PhD, MPP, Elizabeth Richey, BA, James B Bussel

Blood (2008) 112 (11): 3433.

https://doi.org/10.1182/blood.V112.11.3433.3433

Published: 2008

NARROW

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Trends of Palliative Care Utilization in Acute Myeloid Leukemia in the United States

Filgrastim Biosimilar: Curb Your Enthusiasm in the US, and Celebrate in the EU, Canada, and Japan

Darbepoetin Hits a Double As Epoetin Hits a Home Run in Response to the 2007 FDA Black Box Warning

Introduction of a Quick Assay for ADAMTS13 Activity Improved a Survival of Acquired TTP Patients Who Received Platelet Transfusions

Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012)

Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents

Forewarned Is Forearmed- Comparison of Southern Network on Adverse Reactions (SONAR) Versus an FDA-Mandated Prospective Observational Registry Assessment of Gemtuzumab Ozogamycin-Associated Sinusoidal Obstructive Syndrome

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Connecticut Attorney General Blumenthal's Citizen Petition Regarding Thalidomide-Associated VTE Redux: Patient Safety Concerns Still Persist.

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Reactivation of Hepatitis B Virus (HBV) Associated with Rituximab Use in Lymphoma: Under Reporting and Lack of Data Quality Reported to the FDA.

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Multiple Non-Linear Epitopes of ADAMTS13 Were Targeted by Anti- ADAMTS13 IgG in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only